Home » News and Views » #TEK Tek Capital plc – Investee Company #BELL Belluscura plc

#TEK Tek Capital plc – Investee Company #BELL Belluscura plc

Belluscura, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, is delighted to announce that it has won two 2022 HME Business New Product Awards for its X-PLOR® portable oxygen concentrator and Nomad Biometric™ App.


X-PLOR® is a lightweight portable oxygen concentrator (“POC”) with user replaceable oxygen enrichment cartridges and direct-charge batteries. Weighing only 3.75 lbs, its AirgonomicTM Design ensures user-friendly experience and maximum comfort and mobility. It has multiple Pulse Flow Settings including its novel X-PLORATIONTM Mode.


The next generation X-PLOR® also includes the new Nomad Biometric™ App, where patients can connect other Bluetooth® devices such as their iPhone® or Android phone, Nonin® or Masimo® pulse oximeters, and Fitbit® wearables to track healthcare data which can be shared with healthcare providers.


The New Product Award is run by HME Business, part of the HME Media Group, honouring outstanding product development achievements by HME manufacturers and service providers. The competition is judged by a panel of HME providers from a variety of backgrounds and category specialties.


Both products, along with Belluscura’s next generation POC, the DISCOV-R™, will be on display at Medtrade in Atlanta, Georgia between October 24-26. Medtrade is the largest home medical equipment trade show and conference in the US.


The DISCOV-R™, weighing just 6.5lbs when it is launched in Q1 2023, will be the world’s first ambulatory dual flow POC. Comparable competitive devices weigh nearly twice as much and lack Belluscura’s novel NOMAD Biometric App and patented technology.


Robert Rauker, CEO of Belluscura plc, commented:


We are delighted that Belluscura has been awarded two 2022 HME Business New Product Awards for the X-PLOR® portable oxygen concentrator and the Nomad Biometric™ App. The awards recognize the outstanding product innovation behind the X-PLOR®, the Nomad Biometric™ App, and the DISCOV-R™. We look forward to introducing our latest portable oxygen concentrator to the market, DISCOV-R, which, like all our products, was designed with our patients in mind and getting them back to doing the things that they love.”





For further information, please contact:


Belluscura plc


Robert Rauker, Chief Executive Officer

via MHP

Anthony Dyer, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

MHP Communications (Financial PR and Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Pete Lambie / Matthew Taylor

Email: belluscura@mhpc.com



About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.


About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.


Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.